ReviewBioresources and bioprocessing2026
Valorization of ligustrum species: biosynthesis, metabolic engineering, and pharmacology of bioactive compounds.
Review in Bioresources and bioprocessing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The genus Ligustrum (Oleaceae) encompasses woody plants with both medicinal and edible uses, distinguished by a wide range of bioactive compounds, including triterpenoids, phenylethanoid glycosides, flavonoids, and other active constituents. These metabolites demonstrate multi-target pharmacological effects, such as anti-inflammatory, antioxidant, antitumor, and anti-osteoporotic activities. In traditional medicine, species like L. lucidum and L. robustum are well-documented for their therapeutic roles in nourishing the liver and kidneys, enhancing vision, darkening hair, and serving as functional tea ingredients. Beyond their medicinal and health-promoting properties, Ligustrum species are also employed as ornamental plants, bioindicators of atmospheric pollution, algicidal agents, and feed additives. Given the increasing global demand and underutilization of Ligustrum resources, there is an urgent need to establish a sustainable supply framework focused on alternative strategies such as metabolic engineering, synthetic biology, and environmentally friendly manufacturing. This review encapsulates recent progress in the exploration of chemical diversity, pharmacological characteristics, omics-based analyses, and biosynthetic research pertaining to Ligustrum. It proposes an integrated methodology that amalgamates multi-omics approaches, synthetic biology, and environmentally sustainable manufacturing processes to advance strategies for whole-plant valorization and germplasm conservation. The objective is to establish a theoretical framework and technical paradigm to facilitate the comprehensive exploitation and sustainable utilization of Ligustrum as a medicinal resource.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.